Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The current role of platelet-active drugs in ischaemic heart disease.

× No keyword cloud information.

46 in total

1. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus.

Authors: Z R Gan; R J Gould; J W Jacobs; P A Friedman; M A Polokoff
Journal: J Biol Chem Date: 1988-12-25 Impact factor: 5.157

2. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Authors: P Patrignani; P Filabozzi; C Patrono
Journal: J Clin Invest Date: 1982-06 Impact factor: 14.808

3. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin.

Authors: C R Klimt; G L Knatterud; J Stamler; P Meier
Journal: J Am Coll Cardiol Date: 1986-02 Impact factor: 24.094

4. Aspirin use and chronic diseases: a cohort study of the elderly.

Authors: A Paganini-Hill; A Chao; R K Ross; B E Henderson
Journal: BMJ Date: 1989-11-18

5. Acetylation of prostaglandin synthase by aspirin.

Authors: G J Roth; N Stanford; P W Majerus
Journal: Proc Natl Acad Sci U S A Date: 1975-08 Impact factor: 11.205

6. Chemical synthesis of echistatin, a potent inhibitor of platelet aggregation from Echis carinatus: synthesis and biological activity of selected analogs.

Authors: V M Garsky; P K Lumma; R M Freidinger; S M Pitzenberger; W C Randall; D F Veber; R J Gould; P A Friedman
Journal: Proc Natl Acad Sci U S A Date: 1989-06 Impact factor: 11.205

7. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients.

Authors: B B Weksler; S B Pett; D Alonso; R C Richter; P Stelzer; V Subramanian; K Tack-Goldman; W A Gay
Journal: N Engl J Med Date: 1983-04-07 Impact factor: 91.245

8. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group.

Authors:
Journal: Lancet Date: 1990-10-06 Impact factor: 79.321

9. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.

Authors: F De Clerck; J Beetens; A Van de Water; E Vercammen; P A Janssen
Journal: Thromb Haemost Date: 1989-02-28 Impact factor: 5.249

10. Randomised trial of prophylactic daily aspirin in British male doctors.

Authors: R Peto; R Gray; R Collins; K Wheatley; C Hennekens; K Jamrozik; C Warlow; B Hafner; E Thompson; S Norton
Journal: Br Med J (Clin Res Ed) Date: 1988-01-30

1 in total

Review 1. Cardiovascular drugs.

Authors: P Vermeij
Journal: Pharm Weekbl Sci Date: 1992-08-21

1 in total